相似文献
1
Metformin for aging and cancer prevention.
Aging (Albany NY). 2010 Nov;2(11):760-74. doi: 10.18632/aging.100230.
2
The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer.
Crit Rev Oncol Hematol. 2013 Sep;87(3):201-23. doi: 10.1016/j.critrevonc.2013.01.005. Epub 2013 Feb 21.
3
Metformin: do we finally have an anti-aging drug?
Cell Cycle. 2013 Nov 15;12(22):3483-9. doi: 10.4161/cc.26928. Epub 2013 Oct 24.
4
Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens.
Ann N Y Acad Sci. 2005 Dec;1057:220-34. doi: 10.1196/annals.1356.017.
5
Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention.
Exp Gerontol. 2003 Oct;38(10):1041-9. doi: 10.1016/s0531-5565(03)00169-4.
6
[Role of the growth hormone-insulin-like growth factor-1-insulin system signaling in aging and longevity: evolutional aspect].
Ross Fiziol Zh Im I M Sechenova. 2008 Sep;94(9):1092-109.
7
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Exp Gerontol. 2005 Aug-Sep;40(8-9):685-93. doi: 10.1016/j.exger.2005.07.007.
8
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice.
Aging (Albany NY). 2010 Dec;2(12):945-58. doi: 10.18632/aging.100245.
9
Metformin slows down aging and extends life span of female SHR mice.
Cell Cycle. 2008 Sep 1;7(17):2769-73. doi: 10.4161/cc.7.17.6625. Epub 2008 Sep 11.
10
If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.
Aging (Albany NY). 2011 Feb;3(2):148-57. doi: 10.18632/aging.100273.
引用本文的文献
1
The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.
Research (Wash D C). 2025 Mar 5;8:0612. doi: 10.34133/research.0612. eCollection 2025.
2
The combined treatment with ketogenic diet and metformin slows tumor growth in two mouse models of triple negative breast cancer.
Transl Med Commun. 2024;9(1). doi: 10.1186/s41231-024-00178-8. Epub 2024 Jun 22.
3
The combination of metformin and high glucose increased longevity of a DAF-16/FOXO-independent manner: cancer/diabetic model via .
Front Endocrinol (Lausanne). 2024 Nov 4;15:1435098. doi: 10.3389/fendo.2024.1435098. eCollection 2024.
4
The Combined Treatment with Ketogenic Diet and Metformin Slows Tumor Growth in Two Mouse Models of Triple Negative Breast Cancer.
Res Sq. 2023 Dec 20:rs.3.rs-3664129. doi: 10.21203/rs.3.rs-3664129/v1.
5
Lipid and glucose metabolism in senescence.
Front Nutr. 2023 Aug 23;10:1157352. doi: 10.3389/fnut.2023.1157352. eCollection 2023.
6
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
Drug Des Devel Ther. 2023 Jun 26;17:1907-1932. doi: 10.2147/DDDT.S409373. eCollection 2023.
7
Therapeutic Antiaging Strategies.
Biomedicines. 2022 Oct 8;10(10):2515. doi: 10.3390/biomedicines10102515.
8
Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet?
Aging Dis. 2022 Feb 1;13(1):175-214. doi: 10.14336/AD.2021.0705. eCollection 2022 Feb.
9
A Comparative Study of the Lipophilicity of Metformin and Phenformin.
Molecules. 2021 Oct 31;26(21):6613. doi: 10.3390/molecules26216613.
10
Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products.
Molecules. 2021 Apr 10;26(8):2179. doi: 10.3390/molecules26082179.
本文引用的文献
1
[Effect of metformin on the magnitude of oxidative stress in patients with type 2 diabetes mellitus].
Probl Endokrinol (Mosk). 2007 Feb 15;53(1):3-7. doi: 10.14341/probl20075313-7.
2
[Melatonin and metformin inhibit skin carcinogenesis induced by benz(a)pyrene in mice].
Vopr Onkol. 2010;56(5):583-7.
3
Life span extension by resveratrol, rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging.
Biofactors. 2010 Sep-Oct;36(5):377-82. doi: 10.1002/biof.127.
4
Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76. doi: 10.1158/1940-6207.CAPR-10-0055. Epub 2010 Sep 1.
5
Metformin and other biguanides in oncology: advancing the research agenda.
Cancer Prev Res (Phila). 2010 Sep;3(9):1060-5. doi: 10.1158/1940-6207.CAPR-10-0175. Epub 2010 Sep 1.
6
Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond.
Future Oncol. 2010 Aug;6(8):1313-23. doi: 10.2217/fon.10.87.
7
Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Curr Mol Med. 2010 Oct;10(7):674-91. doi: 10.2174/156652410792630625.
8
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Mol Carcinog. 2010 Jul;49(7):662-71. doi: 10.1002/mc.20637.
9
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Expert Rev Mol Diagn. 2010 May;10(4):509-19. doi: 10.1586/erm.10.22.
10
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.
Cell Metab. 2010 May 5;11(5):390-401. doi: 10.1016/j.cmet.2010.03.014.
Zotero 插件